Pharmacologic treatment augmentation in chronic depression randomized, controlled, double blinded, phase II study

Key information made simple

This study is comparing Ketamin Inresa 2 ml with Fresenius Kabi Deutschland GmbH Isotone E NaCL 0.9 for people with Males and females between 18-64 years with a diagnosis of chronic depression. Participants receive Ketamin Inresa 2 ml or Fresenius Kabi Deutschland GmbH Isotone E NaCL 0.9 and complete study visits and assessments. Some participants may receive Fresenius Kabi Deutschland GmbH Isotone E NaCL 0.9 instead of the study treatment, and direct benefit is not guaranteed.

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.